Archive for February 2014
Andarix Receives Orphan Drug Designation from the FDA for Small Cell Lung Cancer
Novel Targeted and Personalized Medicine Approach to Lung Cancer ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and neuroendocrine cancers announced today that Tozaride, the Company’s targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of small…
Read More